The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking

Bone

Volumn 49, Issue 4, 2011, Pages 623-635

  Leung, P ^a   Pickarski, M ^a   Zhuo, Y ^a   Masarachia, P J ^a   Duong, L T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bone resorption; Cathepsin K inhibitor; Osteoclast; Osteoporosis; Transcytosis; Vesicular trafficking

Indexed keywords

ACID PHOSPHATASE; CATHEPSIN K; CATHEPSIN K INHIBITOR; COLONY STIMULATING FACTOR; F ACTIN; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; PAXILLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; BONE MATRIX; BONE STRENGTH; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CELL TRANSPORT; CELL VACUOLE; COLLAGEN DEGRADATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; POLARIZATION; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; TRANSCYTOSIS;

ACID PHOSPHATASE; ANIMALS; BIPHENYL COMPOUNDS; BONE AND BONES; BONE MATRIX; BONE RESORPTION; CATHEPSIN K; CELL POLARITY; CELL SURVIVAL; ENDOCYTOSIS; HUMANS; INTRACELLULAR SPACE; ISOENZYMES; MICE; OSTEOCLASTS; OSTEOGENESIS; PROTEASE INHIBITORS; PROTEIN TRANSPORT; TRANSPORT VESICLES;

EID: 80052279445     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.06.014     Document Type: Article

References (49)

1. Coxon F.P., Taylor A. Vesicular trafficking in osteoclasts. Semin Cell Dev Biol 2008, 19:424-433.
2. Duong L.T., Rodan G.A. Regulation of osteoclast formation and function. Rev Endocr Metab Disord 2001, 2:95-104.
3. Blair H.C., Teitelbaum S.L., Ghiselli R., Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989, 245:855-857.
4. Bromme D., Okamoto K., Wang B.B., Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996, 271:2126-2132.
5. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273:1236-1238.
6. Schilling A.F., Mulhausen C., Lehmann W., Santer R., Schinke T., Rueger J.M., et al. High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K. Osteoporos Int 2007, 18:659-669.
7. Everts V., Aronson D.C., Beertsen W. Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int 1985, 37:25-31.
8. Li C.Y., Jepsen K.J., Majeska R.J., Zhang J., Ni R., Gelb B.D., et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J Bone Miner Res 2006, 21:865-875.
9. Pennypacker B., Shea M., Liu Q., Masarachia P., Saftig P., Rodan S., et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009, 44:199-207.
10. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996, 271:12511-12516.
11. Garnero P., Ferreras M., Karsdal M.A., NicAmhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18:859-867.
12. Stenbeck G., Horton M.A. A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci 2000, 113(Pt 9):1577-1587.
13. Yamaza T., Goto T., Kamiya T., Kobayashi Y., Sakai H., Tanaka T. Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur. Bone 1998, 23:499-509.
14. Gauthier J.Y., Chauret N., Cromlish W., Desmarais S., Duong L.T., Falgueyret J.P., et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008, 18:923-928.
15. Pennypacker B.L., Duong L.T., Cusick T.E., Masarachia P.J., Gentile M.A., Gauthier J.Y., et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2010, 26:252-262.
16. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2010, 26:242-251.
17. Everts V., Delaisse J.M., Korper W., Niehof A., Vaes G., Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 1992, 150:221-231.
18. Wesolowski G., Duong L.T., Lakkakorpi P.T., Nagy R.M., Tezuka K., Tanaka H., et al. Isolation and characterization of highly enriched, prefusion mouse osteoclastic cells. Exp Cell Res 1995, 219:679-686.
19. Masarachia P., Yamamoto M., Leu C.T., Rodan G., Duong L. Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism. Endocrinology 1998, 139:1401-1410.
20. Lakkakorpi P.T., Bett A.J., Lipfert L., Rodan G.A., Duong L.T. PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption. J Biol Chem 2003, 278:11502-11512.
21. Hayami T., Pickarski M., Wesolowski G.A., McLane J., Bone A., Destefano J., et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004, 50:1193-1206.
22. Nesbitt S.A., Horton M.A. Fluorescence imaging of bone-resorbing osteoclasts by confocal microscopy. Methods Mol Med 2003, 80:259-281.
23. Selander K., Lehenkari P., Vaananen H.K. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 1994, 55:368-375.
24. Lindeman J.H., Hanemaaijer R., Mulder A., Dijkstra P.D., Szuhai K., Bromme D., et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004, 165:593-600.
25. Masarachia P., Pun S., Kimmel D. Bone effects of cathepsin K inhibitor in ovariectomized rhesus monkeys. J Bone Miner Res 2007, 22(SUPPL 1).
26. Scott K., Cusick T.E., Duong L.T., Pennypacker B., Kimmel D. Effects of odanacatib on bone turnover and osteoclast morphology in the lumbar vertebra of ovariectomized adult rhesus monkeys. J Bone Miner Res 2009, 24(SUPPL 1).
27. Everts V., Hou W.S., Rialland X., Tigchelaar W., Saftig P., Bromme D., et al. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int 2003, 73:380-386.
28. Mandelin J., Hukkanen M., Li T.F., Korhonen M., Liljestrom M., Sillat T., et al. Human osteoblasts produce cathepsin K. Bone 2006, 38:769-777.
29. Brage M., Abrahamson M., Lindstrom V., Grubb A., Lerner U.H. Different cysteine proteinases involved in bone resorption and osteoclast formation. Calcif Tissue Int 2005, 76:439-447.
30. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999, 14:1654-1663.
31. Kiviranta R., Morko J., Alatalo S.L., NicAmhlaoibh R., Risteli J., Laitala-Leinonen T., et al. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 2005, 36:159-172.
32. Susa M., Luong-Nguyen N.H., Cappellen D., Zamurovic N., Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2004, 2:6.
33. Stroup G.B., Kumar S., Jerome C.P. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int 2009, 85:344-355.
34. Everts V., Korper W., Hoeben K.A., Jansen I.D., Bromme D., Cleutjens K.B., et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 2006, 21:1399-1408.
35. Soe K., Delaisse J.M. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res 2010, 25:2184-2192.
36. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 1998, 95:13453-13458.
37. Votta B.J., Levy M.A., Badger A., Bradbeer J., Dodds R.A., James I.E., et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 1997, 12:1396-1406.
38. Chappard D., Libouban H., Mindeholm L., Basle M.F., Legrand E., Audran M. The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients. Microsc Res Tech 2010, 73:726-732.
39. Li Z., Hou W.S., Bromme D. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry 2000, 39:529-536.
40. McQueney M.S., Amegadzie B.Y., D'Alessio K., Hanning C.R., McLaughlin M.M., McNulty D., et al. Autocatalytic activation of human cathepsin K. J Biol Chem 1997, 272:13955-13960.
41. Mulari M., Vaaraniemi J., Vaananen H.K. Intracellular membrane trafficking in bone resorbing osteoclasts. Microsc Res Tech 2003, 61:496-503.
42. Halleen J.M., Raisanen S., Salo J.J., Reddy S.V., Roodman G.D., Hentunen T.A., et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999, 274:22907-22910.
43. Vaaraniemi J., Halleen J.M., Kaarlonen K., Ylipahkala H., Alatalo S.L., Andersson G., et al. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 2004, 19:1432-1440.
44. Ljusberg J., Wang Y., Lang P., Norgard M., Dodds R., Hultenby K., et al. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 2005, 280:28370-28381.
45. Zenger S., Hollberg K., Ljusberg J., Norgard M., Ek-Rylander B., Kiviranta R., et al. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone 2007, 41:820-832.
46. Perez-Amodio S., Jansen D.C., Schoenmaker T., Vogels I.M., Reinheckel T., Hayman A.R., et al. Calvarial osteoclasts express a higher level of tartrate-resistant acid phosphatase than long bone osteoclasts and activation does not depend on cathepsin K or L activity. Calcif Tissue Int 2006, 79:245-254.
47. Palokangas H., Mulari M., Vaananen H.K. Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts. J Cell Sci 1997, 110(Pt 15):1767-1780.
48. Angel N.Z., Walsh N., Forwood M.R., Ostrowski M.C., Cassady A.I., Hume D.A. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res 2000, 15:103-110.
49. Del Fattore A., Fornari R., Van Wesenbeeck L., de Freitas F., Timmermans J.P., Peruzzi B., et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res 2008, 23:380-391.